Selected Grants
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation MajesTEC-4
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030Celgene: CA057-001 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYE
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Clinical TrialPrincipal Investigator · Awarded by Caribou Biosciences, Inc. · 2023 - 2028A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2023 - 2028K36 Therapeutics: Ph1 KTX-1001 Oral, FIC, MMSET Cat Inhib in Pts w/ RRMM
Clinical TrialPrincipal Investigator · Awarded by K36 Therapeutics · 2023 - 2028Relapsed or Refractory Multiple Myeloma: ABBV-383 vs Standard Available Therapies in Subjects with RRMM (3L+ RRMM Monotherapy Study)
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2025 - 2028A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2022 - 2027First-in-Human Two-Part Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2022 - 2027Role of SLAMF7 in Racial Disparities in Myeloma
ResearchCo Investigator · Awarded by National Cancer Institute · 2023 - 2026Phase Ib/2 Study of Selinexor (KPT330) in combination with Backbone treatment for R/R Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2016 - 2025A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2018 - 2025An Observational Study on Newly Diagnosed MM to assess the realtionship between patient outcomes, treatment regimens
Clinical TrialPrincipal Investigator · Awarded by Multiple Myeloma Research Foundation · 2013 - 2024Relapsed or Refractory Multiple Myeloma: Eftozanermin Alfa (ABBV-621) with Bortezomib and Dexamethasone
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2021 - 2024A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2018 - 2023A Phase 2, Open-label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2018 - 2023A Phase 1, Open Label Study to evaluate the safety Pharmacokinetic, Pharmacodynamic and clinical activity of PF-06863135, A B-Cell Maturation Antigen (BCMA)- CD3 Bispecifi Antibody In Patient
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2018 - 2023FULL TITLE: A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab (TJ011133) with or without Dexamethasone and in Combination with Anti-Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2022 - 2023PTND01DM-D001DM
Clinical TrialPrincipal Investigator · Awarded by Prothena Therapeutics Limited · 2021 - 2023Phase III double blind study of Bortezomib and Dex in combination with Venetoclax or Placebo in R/R MM
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2016 - 2022Phase 2, Randomized, Open-Label Study comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects with Newly Diagnosed Multiple Myeloma Eligible for High dose chemo
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2017 - 2022A Phase I Study of ABT-199 Monotherapy in R/R Multiple Myeloma
ResearchPrincipal Investigator · Awarded by AbbVie Inc. · 2015 - 2022Phase 1/2b study of Ibrutinib with Carlfizomib with R/R Myeloma
Clinical TrialPrincipal Investigator · Awarded by Pharmacyclics, Inc. · 2013 - 2021A Feasibility Phase II study of BEAM followed by MLN 9708 Maintenance therapy in high risk MM patients
Clinical TrialPrincipal Investigator · Awarded by Oregon Health & Science University · 2016 - 2021An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2021Phase 1/2 Open label study of SL-401 with Pom/Dex in R/R MM
Clinical TrialPrincipal Investigator · Awarded by Stemline Therapeutics, Inc · 2016 - 2021Phase III study of Pomalidomide and low dose Dex with or without Pembrolizumab (MK3475) in MM
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2016 - 2021Open-Label, Multicenter, Dose-Escalation Expansion Phase IB study to Evaluate Safety, Pharmacokinetics, and activity of BET Inhibitor RO6870810, Given as Mono- and combination Therapy to patients with Advanced Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2018 - 2020Study to evaluate the safety of SAR650984 (isatuximab) in R/R MM pts
Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2017 - 2019A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (Pronto) previously enrolled in Study NEOD001-201 (PRONTO)
Clinical TrialPrincipal Investigator · Awarded by Prothena Therapeutics Limited · 2017 - 2018A Phase II study of Filanesib (ARRY-520) with patients with Advanced Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Array BioPharma Inc · 2014 - 2018CELGENE MULTIPLE MYELOMA TUMOR PRACTICUM
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Celgene Corporation · 2017 - 2017Randomized Phase II trial study of lenalidomide, bortezomib and dexamethsone (RVD)with or without Panobinostat in new MM pts
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2016 - 2017Phase II, randomized, double-blinded, placebo-controlled multicenter study of Selinexor KPT-330 Carlf, and Dexa, in R/R MM pts who previously have been treated with proteasome inhibitor and an immunomodulatory drug
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2016 - 2017A Multi-center, phase 1/2 open label study of Selinexor (KPT-330), Lenalidomide, and Dexamethasone in patients with R/R MM
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2015 - 2017Dendritic Cell Based Vaccination for Multiple Myeloma
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2002 - 2007External Relationships
- AbbVie, Inc.
- Brystol Myers (celgene)
- GlaxoSmithKline
- Janssen AI (Johnson & Johnson)
- Karyopharm Therapeutics Inc
- Pfizer Inc.
- Sanofi
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.